APOBEC3B and urinary bladder carcinoma: Additionally, our meta-analysis revealed the lack of the association of the APOBEC3B deletion with ovarian cancer [OR(95%CI)=1.070(0.558-2.052), p=0.839] and opposite association (protective effect) of the deletion with bladder cancer [OR(95%CI)=0.834(0.734-0.948), p=0.005].